INTRODUCTION
Over the past 3 years, significant changes in the management of castration-resistant prostate cancer (CRPC) patients have occurred. Although newly developed agents have different targets, they all seemed to impact outcome in a favorable way. Similar challenges, however, exist. Timing of their use, measure of their efficacy, expected adverse events and economics are some of the key questions posted during their development process. Some of the biological questions of the disease have been addressed by the novel adrenal inhibitor abiraterone acetate and the receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor denosumab; however, there is no clear understanding as to the true biologic effect of sipuleucel-T. As for cabazitaxel, the unexpected results of an old and forgotten microtubule inhibitor have emphasized again the importance of cytotoxic therapy in this disease. The future of prostate cancer (PCa) patients is brighter than ever as the understanding of the biology of the disease continues to grow, allowing a continued expansion of research opportunities in a disease in which castration appeared to be the only therapeutic approach available. In this review, the development of four newly US Food and Drug Administration (FDA)-approved agents for CRPC will be discussed.
SIPULEUCEL-T: IS IT REALLY WORTH IT?
Over the past several years, immunotherapy has gained momentum as a potential therapeutic strategy in PCa. The natural history of the disease and the availability of tumor-specific antigens such as prostatic acid phosphatase (PAP) have permitted the development of various immune approaches. Among those is sipuleucel-T, an autologous active cellular immunotherapy product designed to stimulate an immune response against PCa.
Sipuleucel-T consists of autologous peripheral blood mononuclear cells, including antigenpresenting cells (APCs) pulsed ex vivo and activated in vitro with PA2024. The recombinant fusion protein, PA2024, is composed of a full-length PAP linked via its COOH terminus to the NH 2 terminus of full-length granulocyte macrophage colonystimulating factor (GM-CSF) [1, 2] .
Multiple phase I/II sequential trials evaluated the immune effects of sipuleucel-T in patients with CRPC. Treatment with sipuleucel-T generated a T-cell response defined by the immune response to the recall antigen influenza and to the naive antigen keyhole limpet hemocyanin. Although there was no obvious correlation between dose infused and the magnitude of T-cell proliferation, T-cell responses were maximal after either two or three infusions of sipuleucel-T. Similarly, almost half of patients treated with sipuleucel-T developed antibodies to PAP and GM-CSF when compared with baseline [3] . Initial phase III trials evaluating the clinical activity of sipuleucel-T in men with metastatic CRPC included D9901 and D9902A, two identical, randomized, double-blind, placebo-controlled studies [4, 5] . Both trials used time to progression (TTP) as their primary endpoint and randomized in a 2 : 1 fashion a total of 225 patients (127 in D9901 and 98 in D9902A) to either sipuleucel-T or placebo. On disease progression, placebo patients received a similar product made with frozen leukopheresis cells. When the results of D9901 were reported, D9902A was prematurely stopped. Both trials obtained imaging studies every 8 weeks until week 32 then every 12 weeks thereafter, and progression was confirmed by independent review. PSA was not used to determine disease progression or to trigger radiographic evaluations. The median TTP for patients receiving sipuleucel-T in study D9901 was 11.7 weeks compared with 10.0 weeks for placebo [log-rank P ¼ 0.052, hazard ratio 1.45, 95% confidence interval (CI) 0.99-2.11] [4] . Similarly, the TTP in the D9902A was 10.9 and 9.9 weeks, respectively (log-rank P ¼ 0.719, hazard ratio 1.09, 95% CI 0.69-1.70) [5] . PSA responses defined by a PSA reduction of more than 50% compared with baseline were only observed in less than 5% of patients. No response evaluation criteria in solid tumor defined objective responses were reported. Although overall survival (OS) was not the primary endpoint of the study, the median OS in the D9901 study was 25.9 months for sipuleucel-T-treated patients and 21.4 months for placebo (log-rank P ¼ 0.01, hazard ratio 1.70, 95% CI 1.13-2.56). No survival benefit was observed in D9902A; however, when both trials were analyzed together, the median OS was 23.2 months for sipuleucel-T and 18.9 months for placebo (P ¼ 0.011). This OS benefit was maintained after adjusting for multiple predefined CRPC prognostic factors [6, 7] including the subsequent use of docetaxel-based chemotherapy (P ¼ 0.022) [5] .
To confirm the OS benefit observed in previous studies, a subsequent double-blind, placebocontrolled, multicenter trial, called the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study, was conducted [8 && ]. This trial randomized 512 metastatic CRPC patients with asymptomatic or minimally symptomatic disease and used similar statistical designs as previous phase III trials. Contrary to previous studies, OS was the primary endpoint of the trial. The median OS was 25.8 months for sipuleucel-T-treated patients compared with 21.7 months for patients receiving placebo with an adjusted hazard ratio for death of 0.78 (95% CI 0.61-0.98), representing a relative reduction in the risk of death of 22% (P ¼ 0.03). This benefit was observed regardless of stratification. The overall response rate (ORR) was observed in less than 5% of patients and as documented in previous studies less than 3% of patients achieved a PSA decline of 50% or less when compared with baseline.
KEY POINTS
Androgen receptor (AR) continues to be the major driver in the setting of CRPC.
Although immunotherapy with sipuleucel-T improves median overall survival (OS) of CRPC, it does not impact prostate specific antigen (PSA), clinical symptoms or objective disease.
Adrenal androgens can activate Androgen receptor and, thus, selective inhibition of the cytochrome P450-17 pathway with abiraterone acetate has shown significant activity in CRPC.
Bone health remains crucial in elderly men with prostate cancer. Bone-targeted therapy at different stages of the disease has shown to improve outcome.
Second-line chemotherapy with cabazitaxel improves OS; however, careful management and prevention of Adverse events (AEs) is required.
When determining the biologic effects of this compound in this population of patients, all phase 3 trials evaluated antibody titers and T-cell proliferation. Almost 60% of patients developed antibodies against PAP2024. At week 6 of treatment on the IMPACT trial, T-cell proliferation responses (stimulation index >5) to PAP2024 were observed in 73% of patients treated with sipuleucel-T group compared with 12% in the placebo group. No changes in the immune correlative studies conducted in any of these trials correlated with outcome.
Despite its lack of toxicity and OS benefit data, the FDA approval of sipuleucel-T has generated significant controversy among the PCa community. Using traditional markers of response to treatment in CRPC, there is no evidence that sipuleucel-T exerts a measurable antitumor activity. Sipuleucel-T's impact on the natural history of the disease is somewhat perplexing as well and there is no evidence of tumor burden reduction after treatment with this immune compound. Perhaps the most important question of all is the mechanism by which sipuleucel-T improves OS. The presumption that this immune product works by activating APCs, which in turn will prime and activate T-cell function, ultimately leading to antitumor activity, requires further validation. Similarly, the timing of its use and the most appropriate patient population likely to derive the greatest benefit from this agent remain not well defined.
Existing efforts to understand the cost-effectiveness of this agent and the potential to expand to other active immune approaches continues. With the availability of other novel compounds capable of impacting PSA and ORR, the utility of sipuleucel-T will remain isolated to those who truly believe in the long-lasting effects of this novel immune approach.
ABIRATERONE ACETATE: IMPORTANCE OF ADRENAL ANDROGENS IN CASTRATION-RESISTANT PROSTATE CANCER
The AR is a member of the nuclear receptor superfamily that acts as a ligand-dependent transcription factor and modulates the growth and development of prostate epithelial cells [9] . The role of Androgen receptor in CRPC has been extensively studied. Despite initial data suggesting the loss of Androgen receptor activity in this setting, AR overexpression in tissue specimens from castrate-resistant tumors indicates the importance of this gene even in the context of a testosterone-deprived state [10] . Although AR appears to be the common denominator, biologically, the development of CRPC can not be related to a single event. Some of the working mechanisms currently undergoing investigation include the activation of Androgen receptor via a ligand-independent manner, [10, 11] or with changes in the level of intratumoral ligand(s). AR gene amplification and changes in Androgen receptor coregulatory molecules and activating Androgen receptor mutations are some of the other proposed hypotheses [12] [13] [14] [15] .
Modern data demonstrate that even at low levels, intratumoral or adrenal androgens can activate Androgen receptor and promote PCa growth and survival [16] [17] [18] . In fact, 5-10% of circulating testosterone in humans is synthesized in the adrenal glands. In castrate prostate tumor tissues, levels of dehydroepiandrosterone (DHEA), DHEA-S and 5-androstenediol exceed the concentrations of testosterone and dehydrotestosterone (DHT) and can activate wild-type and mutant AR [19] . Additionally, in-vitro and in-vivo data also suggest that adrenal androgens such as DHEA and androstenedione can be metabolized and converted to DHT in PCa cell lines and benign prostatic tissue. These facts have led to the testing of agents that inhibit adrenal steroidogenesis as therapy for CRPC. Obsolete surgical approaches such as adrenalectomy [22] were replaced with the use of nonspecific inhibitors of the adrenal androgen synthesis, such as aminoglutethimide and ketoconazole [20] [21] [22] [23] [24] . Ketoconazole inhibits the conversion of cholesterol to pregnenolone and other cytochrome P-450 enzymes such as cytochrome P450-17 (CYP) and 11b-hydroxylase, an enzyme responsible for cortisol synthesis. The clinical efficacy and safety of the antifungal agent ketoconazole has been extensively studied. Treatment with ketoconazole leads to a PSA decline of greater than 50% in a large number of patients (46-62%) . These responses are irrespective of the antiandrogen withdrawal (AAWD) phenomenon. CALGB 9583, a randomized phase III trial, investigated the use of AAWD with or without the addition of ketoconazole in men with CRPC [25] and demonstrated a PSA response of 50% or greater in 27% of patients treated with ketoconazole and AAWD as compared with 11% of those treated with AAWD alone (P ¼ 0.002). The corresponding objective response rate was 20 and 2%, respectively (P ¼ 0.02), and no difference in OS was seen (15.3 vs. 16.7 months, respectively, P ¼ 0.936). Unfortunately, ketoconazole is not a selective adrenal inhibitor and by its effect on the cortisol production pathway, it can lead to adrenal insufficiency, thus the need for replacement doses of steroids in all patients.
Abiraterone acetate is a potent, oral selective inhibitor of CYP17 and 17a-hydroxylase and C17, 20-lyase. Abiraterone acetate is capable of reducing androgenic steroid production downstream from CYP17 [26] . Contrary to ketoconazole, the incidence of adrenal insufficiency with abiraterone acetate is quite low. Early phase I and II studies demonstrated the maximum tolerated dose and safety of this novel compound [27, 28] . Anticipated toxicities included hypertension, hypokalemia and lower extremity edema, all of which were attributable to a syndrome of secondary mineralocorticoid excess, which is easily manageable with eplerenone or low-dose corticosteroids [28] . Despite the wide dose range of abiraterone acetate, the selected dose level for further development was defined as 1000 mg/day after the observation that levels of corticosterone and deoxycorticosterone plateau at doses greater than 750 mg.
The clinical activity of abiraterone acetate was quite robust with a significant number of patients enrolled in these studies achieving a decline in PSA of at least 50% when compared with baseline PSA values. Similarly, the ORR observed in other trials has ranged from 25 to 60% [28, 29] .
Last year, the results of COU-AA301, a randomized, double-blind, placebo-controlled phase III trial of abiraterone acetate with prednisone vs. placebo and prednisone in chemotherapy-refractory metastatic CRPC were reported [30 && ]. Docetaxelrefractory, metastatic CRPC patients were randomized in a 2 : 1 fashion to receive abiraterone acetate 1000 mg/day with prednisone 5 mg twice a day (N ¼ 797) or placebo/prednisone (N ¼ 398). The median age was 69 years, approximately 11% of patients were having Easter Cooperative Oncology Group performance status of 2 and less than 30% of patients had received more than two previous chemotherapy regimens. Almost 90% of patients had bone metastases, 40-45% nodal disease and less than 30% had visceral disease including liver or lung. All patients were stratified based upon performance status, pain, number of prior chemotherapy regimens and type of progressive disease (PSA only vs. radiographic regardless of PSA). The median OS for patients treated in the abiraterone/ prednisone arm was 14.8 months compared with 10.9 months for the patients in the prednisone/ placebo arm (hazard ratio 0.646, P < 0.0001). This benefit was observed across all patients regardless of performance status, sites of metastatic disease and number of prior chemotherapy regimens received. In fact, the median OS for patients who received one or two prior chemotherapy regimens was 15.4 vs. 11.5 months and 14 vs. 10.3 months, respectively. The PSA response rate was 38 vs. 10% favoring abiraterone acetate (P < 0.0001). Equally, treatment with abiraterone acetate significantly delay radiographic progression-free survival (PFS) (5.6 vs. 3.6 months, hazard ratio 0.67, P < 0.0001). As observed in previous studies, AEs were mainly related to the mineralocorticoid excess syndrome associated to this agent. In this study, less than 15% of patients receiving abiraterone acetate developed G3 and G4 AEs, including liver dysfunction, hypokalemia, fluid retention, hypertension and cardiac disorders. Timing to initiate abiraterone acetate is now undergoing further evaluation. A similar randomized, double-blind, placebo-controlled phase III study (COU-AA-302) evaluating abiraterone acetate/prednisone vs. prednisone/placebo in over 1000 patients with chemotherapy-naive asymptomatic or mildly symptomatic metastatic CRPC has completed accrual and is currently undergoing analysis. Similarly, other trials evaluating abiraterone acetate in the CRPC-PSA only disease as well as in the neoadjuvant setting or in combination with standard radiation therapy for patients with either localized or locally advanced PCa are underway and should help to define the role of this novel CYP17 inhibitor in earlier stages of the disease.
SECOND-LINE CHEMOTHERAPY WITH CABAZITAXEL
Until recently, the treatment of men with docetaxelrefractory metastatic CRPC was a therapeutic challenge and an unmet clinical need, as no treatment had demonstrated survival benefit. Mitoxantrone/ prednisone had become the de facto second line of choice primarily for its palliative effects and improvement in quality of life, which was initially observed in front-line studies [31, 32] . Various other cytotoxics explored in the docetaxel-refractory setting have included the epothilones and platinum compounds. Results of a phase II study evaluating the combination of mitoxantrone/prednisone with ixabepilone in docetaxel-refractory patients recently demonstrated a PSA decline of at least 50% in 45% of patients [33] . Among those with measurable disease, the ORR was 22%. Median time to PSA or objective progression was 4.4 months (95% CI 3.5-5.6), and median PFS was also 4.4 months (95% CI 3.0-6.0). The observed median OS was 12.5 months (95% CI 10.2-15.9). Although this combination led to grade 3 and 4 neutropenia with 11% of patients developing neutropenic fever, a phase III study evaluating this combination is planned.
Perhaps the most promising agent that was tested in a phase III setting was satraplatin, a third-generation oral platinum that early on demonstrated some intriguing activity in CRPC patients.
The Satraplatin and Prednisone against Refractory Cancer (SPARC) trial was a randomized (2 : 1, satraplatin:placebo), placebo-controlled, phase III trial designed to investigate the efficacy of satraplatin with prednisone in men (N ¼ 950) with metastatic CRPC who had progressed after at least one chemotherapy regimen [34] . Although the primary endpoint of the study, PFS, was significantly longer with satraplatin (11.1 vs. 9.7 weeks, P < 0.001), there was no difference in OS (61.3 vs. 61.4 weeks, hazard ratio 0.98, 95% CI 0.84-1.15, P ¼ 0.80) and, therefore, did not gain FDA approval in the USA.
Recently, cabazitaxel, a semisynthetic, tubulinbinding taxane drug with demonstrated antitumor activity in models resistant to paclitaxel and docetaxel [35] [36] [37] , became the first FDA-approved agent for the management of patients with docetaxelrefractory metastatic CRPC.
Initial phase I/II studies demonstrated the maximum tolerable dosage and safety of this compound and showed that neutropenia and diarrhea were the primary dose-limiting toxicities [38, 39] . These studies also suggested antitumor activity in solid tumors, including docetaxel-refractory metastatic CRPC.
The clinical activity of cabazitaxel in the secondline setting was evaluated in the phase III TROPIC trial [40 && ]. Over 750 metastatic CRPC patients who had disease progression during or after treatment with docetaxel were randomly assigned to prednisone (10 mg/day) with either cabazitaxel (25 mg/m 2 ) or mitoxantrone (12 mg/m 2 ) (mitoxantrone/prednisone), with the primary endpoint of OS. The median OS was 15.1 months (95% CI 14.1-16.3) in the cabazitaxel/mitoxantrone group and 12.7 months (95% CI 11.6-13.7) in the mitoxantrone/prednisone group. The hazard ratio for death of men treated with cabazitaxel/mitoxantrone compared with those taking mitoxantrone/prednisone was 0.70 (95% CI 0.59-0.83, P < 0.0001). The ORR for patients with measurable disease was 14.4 vs. 4.4% (P ¼ 0.0005). Equally, the PSA response rate (PSA decline !50%) was 39.2 vs. 17.8% (P ¼ 0.0002). Of concern was the high incidence (82%) of G3 and G4 neutropenia observed in patients receiving cabazitaxel. Febrile neutropenia occurred in 8% of these patients and diarrhea was reported in 6%. There was significant mortality associated with the use of this agent. Eighteen patients in the cabazitaxel arm died from treatment-related AEs, including neutropenic fever, cardiac events, dehydration, renal failure and a hemorrhagic cerebrovascular accident.
Despite the significant OS benefit in this setting, the toxicity profile of cabazitaxel is noteworthy. On the basis of the hematological AEs observed in this study, the prophylactic use of growth factors is mandatory in all patients regardless their risk of developing neutropenia. Currently, two randomized phase III trials evaluating a lower dose of cabazitaxel (20 mg/m 2 ) in the first-line and secondline setting have been initiated.
With the availability of the oral agent abiraterone acetate, patient selection for either chemotherapy of hormonal therapy remains unknown. It is important to note, however, that the likelihood of benefit with cabazitaxel is low when patients receive less than three cycles of docetaxel-based chemotherapy. Similarly, the likelihood of benefit to abiraterone is low when patient's biology is not driven by adrenal androgen production. Several translational studies are currently evaluating the mechanisms of resistance to abiraterone that are often seen early on in patients with a history of rapid progressive disease on standard hormonal therapies.
BONE HEALTH IN PROSTATE CANCER: BONE LOSS VS. SKELETAL RELATED EVENTS
Skeletal complications of PCa have been extensively studied. These complications migrate parallel to the natural history of the disease. Therefore, in the setting of nonmetastatic disease in which men are castrated, the main concern is bone loss. As the disease progressed the questions changed and include bone metastases prevention and the reduction of skeletal-related events in the setting of metastatic hormone responsiveness or CRPC. Historically, PCa is a disease of the elderly and, thus, the vulnerability of this patient population. Although the lifetime risk of a man developing an osteoporotic fracture is less than 20% [41] , the presence of hypogonadism as a result of PCa treatment accelerates loss of bone mineral density and, thus, increases the risk of osteoporotic fractures. Contemporary studies have shown the detrimental effects of castration (surgical or medical) on bone health. In the first year alone when testosterone levels are less than 50 ng/ml, the bone mineral density decline at the lumbar spine and the hip are approximately 3 and 2%, respectively [42] [43] [44] . It is clear that this risk increased with age; thus, older men are at greater risk when receiving testosterone suppression therapy [45] .
To date, three different classes of agents including bisphosphonates (zoledronic acid), RANK-L inhibitors (denosumab) and selective estrogen receptor modulators (toremifene) have been shown to reduce the complications of treatment-induced osteoporosis. With the exception of denosumab, trials evaluating bisphosphonate therapy as preventive measures in men undergoing testosterone suppression were poorly designed and lacked the statistical power and sample size required to detect significant differences among them [45] [46] [47] .
Denosumab, a fully human monoclonal antibody that specifically binds to nuclear factor kappa-B (NF-kB) ligand, a major player in osteoclast formation, function and survival, recently gained FDA approval to prevent bone loss in men undergoing testosterone suppression for PCa [48 && ]. The effects of denosumab were evaluated in a randomized international phase III study of over 1400 men undergoing testosterone suppression therapy for nonmetastatic hormone-responsive PCa. Patients received either denosumab 60 mg subcutaneously or placebo every 6 months. Patients were stratified according to age and duration of androgendeprivation therapy. All patients were required to take daily supplements of calcium and vitamin D. The primary endpoint was the percentage change in the baseline bone mineral density (BMD) of the lumbar spine at 24 months. Other secondary endpoints included the percentage of BMD change at 36 months and the incidence of newly diagnosed vertebral fractures at 36 months. All patients underwent BMD of the lumbar spine, femoral neck and total hip at baseline and at months 1, 3, 6, 12, 24 and 36. At 24 months, treatment with denosumab was associated with increased BMD of 6.7% age points over that in the placebo group (5.6 vs. À1.0%, P < 0.001). Similarly, BMD at the lumbar spine was significantly increased with denosumab at 1 month, and continued to increase through 36 months, as compared with placebo (P < 0.001 at all measured time points). When evaluating markers of bone turnover, serum levels of serum C-telopeptide, procollagen type I N-terminal peptide and tartrate resistant acid phosphatase 5b were decreased from the baseline values by a median of 45, 61 and 33%, respectively, in the denosumab group as compared with 13, 18 and 8%, respectively, in the placebo group (P < 0.001). Treatment with denosumab was well tolerated and when compared with placebo there was no difference in treatment-related AEs. No adverse effects in renal function were reported.
Although osteoporotic fractures related to androgen deprivation therapy-induced hypogonadism are not often seen in the clinical setting, when present they could lead to significant morbidity in elderly men suffering from PCa. Treatment with denosumab in this setting is now a viable alternative that will likely become more appealing as the data in CRPC mature. It is important however to differentiate, the goals of the treatment, as this will impact the dose and schedule of administration.
A more relevant area to use this agent is perhaps the castration-resistant setting. Treatment with denosumab has shown to reduce skeletal-related complications from bone metastases in the castrateresistant setting and also delay radiographic progression patients with CRPC-PSA only disease [49, 50 && ]. Prior to the FDA approval of denosumab, existing evidence supported the use of zoledronic acid (4 mg every 3-4 weeks) to reduce skeletal-related events in men with CRPC and bone metastases. Optimal timing, schedule and duration of bisphosphonate treatment in men with bone metastases have not been well defined.
With the understanding that excess of osteoclastic activity contributes to bone destruction and the recognition of RANK as the major driver of this function, a randomized phase III trial comparing zoledronic acid with denosumab was conducted. In this study, over 1900 patients with bisphosphonatenaive metastatic CRPC were randomized 1 : 1 to either denosumab 120 mg subcutaneously or zoledronic acid 4 mg intravenously on a 4-week schedule [49] . The primary endpoint was time to first on-study skeletal-related event and was assessed for noninferiority. The study planned to test the same endpoint for superiority if testing of the primary endpoint showed noninferiority. Treatment with denosumab significantly delayed the time to first on-study skeletal-related event by 18% compared with zoledronic acid. Denosumab also significantly delayed the time to first and subsequent on-study skeletal-related events. There was no difference in OS between the groups and no impact in other intermediate efficacy endpoints, such as PSA and ORR. No major differences in AEs were observed between the groups. A higher incidence of hypocalcemia was observed in those treated with denosumab (68 vs. 56% of patients). Denosumab did not impact renal function; however, flu-like symptoms including back pain, nausea, fatigue and anorexia were less compared with those commonly observed with zoledronic acid (8.7 vs. 20.2%, respectively). The incidence of all grades of hypocalcemia was 18% with denosumab and 9% with zoledronic acid. There was no significant difference in the rate of osteonecrosis of the jaw (1.8 vs. 1.3%, respectively). Most patients developing this complication had a history of tooth extraction, poor oral hygiene or use of a dental appliance.
Although this agent has not largely replaced zoledronic acid in this setting, recent published data demonstrating the ability of denosumab to delay radiographic progression over placebo [50 && ] will likely impact the perception of this agent in the broad context of CRPC. Prior to this study, no other agent had demonstrated that targeting bone microenvironment could delay the development of bone metastases. In this recent trial, Smith et al.
randomized over 1400 patients with nonmetastatic CRPC considered at high-risk for developing bone metastases (PSA !8 or PSA doubling-time 10 months or both) to either denosumab standard dose and schedule or placebo. The primary and secondary endpoints were assessed hierarchically. The secondary endpoint of time to first bone metastasis was tested only if the primary endpoint of bone metastasis-free survival was significant in favor of denosumab. Similarly, if time to first bone metastasis was also significant in favor of denosumab, OS was to be tested. Treatment with denosumab significantly increased bone metastasis-free survival by a median of 4. As previously reported, biochemical markers of bone turnover decreased significantly with denosumab treatment compared with placebo. Similar to that observed in previous phase III trials, the most common AEs included flu-like symptoms, hypocalcemia and osteonecrosis of the jaw. The latter occurred in 33 (5%) men receiving denosumab at rates of 1 (n ¼ 8), 3 (n ¼ 21) and 4% (n ¼ 30) at end of years 1, 2 and 3, respectively; No osteonecrosis of the jaw occurred in patients on placebo. This is indeed the first prospective study that demonstrates the ability of delaying radiographic progression, the fact that OS was not different suggests that neither PSA or objective disease can be utilized as 'unique' potential surrogates for treatment efficacy especially when OS remains the goal standard for drug development in CRPC.
CONCLUSION
Significant changes in the modern management of PCa have occurred. An unprecedented number of novel agents have been recently added into our armamentarium. More exciting times are coming with the development of agents such as MDV3100, octeronel and cabozantinib, among others. Despite these great developments, we continue to face the same challenges as before. We are dealing with a disease with a uniquely long natural history, we continue to rely on an imperfect tool such as PSA and there is no clear consensus as to the appropriate timing to initiate androgen-deprivation or any subsequent therapy for that matter. Similarly, the cost of many, if not all, of these agents has become somewhat prohibitive for most patients and when one look at the true cost-effectiveness and overall benefit of some of these agents, one has to wonder whether putting patients and the system through the financial constraints of utilizing these agents, either together or in sequence, ultimately is the best approach to their disease. Although we continue sorting some of these logistical and, perhaps, ethical concerns, we continue determined to develop newer and more effective agents that can be utilized in a logical and more appropriate manner. Better and more robust translational programs are needed to define treatments in a more personal manner with the ultimate goal of eradicating this disease.
